Biomarkers of Diet-microbiota Interactions in Irritable Bowel Syndrome

NCT04364750 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-13

No results posted yet for this study

Summary

Most patients suffering from the irritable bowel syndrome (IBS) report that ingestion of certain foods is a major trigger of symptoms, but the reason is unclear. Previous studies have shown that foods containing poorly absorbed carbohydrates (FODMAPs) are fermented by the bacteria in our bowels and these cause symptoms in some but not all patients. Gut bacteria are capable of producing various products, such as neuroimmune mediator histamine, that may be related to IBS symptoms. Our recent data suggest that consumption of FODMAPs promotes production of bacterial histamine.

The main objective of this study is to investigate bacterial production of histamine and its relationship to IBS symptoms. The study will involve 6 weeks on a low-FODMAP diet with three three-day interventions consisting of High- or Low-FODMAP drinks along with probiotics or placebo capsules. The patient's bacteria and metabolites will be analyzed at various time points.

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

L-Histidine

1 capsule (0.6g) twice daily

DIETARY_SUPPLEMENT

High-FODMAP beverage

High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.

DIETARY_SUPPLEMENT

Low-FODMAP beverage

Low-FODMAP beverage (10g glucose) consumed twice daily.

DIETARY_SUPPLEMENT

Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.

Total of 50 billion CFU/capsule taken twice daily.

OTHER

Placebo

Enteric coated capsule with no active ingredient, taken twice daily

Sponsors & Collaborators

Principal Investigators

  • Premysl Bercik, MD · McMaster University

  • Stephen Vanner, MD · Queens University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-15
Primary Completion
2026-02-10
Completion
2026-02-10

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04364750 on ClinicalTrials.gov